Access
This article is part of Nature's premium content.
Published online 11 November 2008 | Nature | doi:10.1038/news.2008.1220
News
Gene-testing company fights to retain listing
Frozen assets compound deCODE's financial woes.
Beleaguered genomics company deCODE Genetics of Reykjavik, Iceland, is preparing to plead its case to a panel that could grant it a reprieve from being delisted from the NASDAQ stock exchange.
On 18 December, the NASDAQ Listing Qualifications Panel will hear how deCODE plans to comply with the rule that requires a minimum capitalization of US$50 million (See 'Icelandic biotech feels the pinch.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
